Chi Wang1, Qi Wang1, Rui Li1, Jun Qin2, Lei Song2, Qian Zhang1, Mingwei Liu2, Jiying Chen1, Chengbin Wang1. 1. Departments of Clinical Laboratory Medicine (Chi Wang, Q.W., Q.Z., and Chengbin Wang) and Orthopedics (Q.W., R.L., and J.C.), People's Liberation Army General Hospital, Beijing, People's Republic of China. 2. State Key Laboratory of Proteomics, National Center for Protein Sciences (The PHOENIX Center), Beijing Proteome Research Center, Beijing, People's Republic of China.
Abstract
BACKGROUND: Diagnosing periprosthetic joint infection (PJI) requires various laboratory and clinical criteria. The purpose of this study was to explore novel biomarkers that could rapidly diagnose PJI with high accuracy. METHODS: In this retrospective study of prospectively collected samples, 50 synovial fluid aspirates, 20 from the hip and 30 from the knee, were collected before surgery; 25 of the patients were diagnosed as having aseptic loosening (non-PJI) and 25, as having PJI according to the Musculoskeletal Infection Society criteria. A quadrupole orbital-trap mass spectrometry (MS) instrument was used to compare expression of proteins in patients with and without PJI. Proteins that were most efficacious for diagnosis of PJI were then determined using prediction analysis of microarray software and a random forest model. The most promising proteins were selected, and altered expression of these selected proteins was verified by ELISA (enzyme-linked immunosorbent assay) in an extended sample cohort. RESULTS: A total of 256 proteins were significantly upregulated (≥3.0-fold) and 14 proteins were downregulated in synovial fluid of patients with PJI compared with patients without PJI. The 3 most promising proteins were lactoferrin (LTF), polymorphonuclear leukocyte serine protease 3 (PRTN3), and myeloid nuclear differentiation antigen (MNDA). When MS was used for diagnosis of PJI, the area under the curve was 0.9888 for LTF, 0.9488 for PRTN3, and 0.9632 for MNDA. ELISA results verified that LTF, MNDA, and PRTN3 were sensitive, while LTF and MNDA were specific, for diagnosis of PJI. CONCLUSIONS: This proteomic study identified a previously noted protein and 2 novel candidate proteins as promising synovial fluid biomarkers for PJI diagnosis, and they should be further validated in future clinical trials. LEVEL OF EVIDENCE: Diagnostic Level III. See Instructions for Authors for a complete description of levels of evidence.
BACKGROUND: Diagnosing periprosthetic joint infection (PJI) requires various laboratory and clinical criteria. The purpose of this study was to explore novel biomarkers that could rapidly diagnose PJI with high accuracy. METHODS: In this retrospective study of prospectively collected samples, 50 synovial fluid aspirates, 20 from the hip and 30 from the knee, were collected before surgery; 25 of the patients were diagnosed as having aseptic loosening (non-PJI) and 25, as having PJI according to the Musculoskeletal Infection Society criteria. A quadrupole orbital-trap mass spectrometry (MS) instrument was used to compare expression of proteins in patients with and without PJI. Proteins that were most efficacious for diagnosis of PJI were then determined using prediction analysis of microarray software and a random forest model. The most promising proteins were selected, and altered expression of these selected proteins was verified by ELISA (enzyme-linked immunosorbent assay) in an extended sample cohort. RESULTS: A total of 256 proteins were significantly upregulated (≥3.0-fold) and 14 proteins were downregulated in synovial fluid of patients with PJI compared with patients without PJI. The 3 most promising proteins were lactoferrin (LTF), polymorphonuclear leukocyte serine protease 3 (PRTN3), and myeloid nuclear differentiation antigen (MNDA). When MS was used for diagnosis of PJI, the area under the curve was 0.9888 for LTF, 0.9488 for PRTN3, and 0.9632 for MNDA. ELISA results verified that LTF, MNDA, and PRTN3 were sensitive, while LTF and MNDA were specific, for diagnosis of PJI. CONCLUSIONS: This proteomic study identified a previously noted protein and 2 novel candidate proteins as promising synovial fluid biomarkers for PJI diagnosis, and they should be further validated in future clinical trials. LEVEL OF EVIDENCE: Diagnostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Authors: Imre Sallai; Nikolett Marton; Attila Szatmári; Ágnes Kittel; György Nagy; Edit I Buzás; Delaram Khamari; Zsolt Komlósi; Katalin Kristóf; László Drahos; Lilla Turiák; Simon Sugár; Dániel Sándor Veres; Daniel Kendoff; Ákos Zahár; Gábor Skaliczki Journal: PLoS One Date: 2022-05-09 Impact factor: 3.752
Authors: Cody R Fisher; Harold I Salmons; Jay Mandrekar; Kerryl E Greenwood-Quaintance; Matthew P Abdel; Robin Patel Journal: Sci Rep Date: 2022-09-27 Impact factor: 4.996
Authors: André Busch; Marcus Jäger; Florian Dittrich; Alexander Wegner; Stefan Landgraeber; Marcel Haversath Journal: J Orthop Surg Res Date: 2020-05-27 Impact factor: 2.359